BMY: Growth Portfolio Momentum Masks Eliquis Policy Cliff – Wait for Margin Proof

What happened

Bristol-Myers Squibb's growth portfolio now accounts for 54.1% of revenues and grew 9% YoY in FQ1'26, but this masks the underlying cliff from Eliquis and Opdivo LOE risks and policy resets. The company's conservative FY2026 guidance could see upside if the growth portfolio sustains momentum and Opdivo Qvantig gains traction, but the DeepValue report flags gross margin as the critical observable metric. Strategic partnerships and M&A support portfolio renewal, yet the near-term revenue and earnings trajectory remains hostage to IRA price-setting and Revlimid's step-function erosion after January 31, 2026. The dividend remains well-covered by free cash flow, yet the stock's valuation at ~$60.46 offers limited upside without confirmation that the Eliquis bridge holds without margin degradation. Investors should wait for Q1-Q2 2026 results to verify that Eliquis growth meets guidance without gross margin slipping below 69%; only then does the risk/reward improve toward the $65 base case.

Implication

If BMY demonstrates margin stability in the first half of 2026, the stock could re-rate toward $65-70 as pipeline catalysts in 2H26 de-risk the post-cliff growth trajectory.

Thesis delta

The article's upbeat tone on growth portfolio strength may lead some to underestimate the fragility of the Eliquis bridge. Our analysis reaffirms that gross margin, not revenue mix, is the true test. The thesis shifts from 'buy the transition' to 'wait for margin proof' as the Eliquis policy overhang becomes observable in Q1'26 results.